Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Background: The standard treatment for unresectable non-small cell lung cancer (NSCLC) is anti-PD-L1 therapy combined with chemoradiotherapy (anti-PD-L1-CRT). Although some patients achieve complete cancer eradication and cure, more than half of patients retain persistent cancer cells. Our research aimed to unravel the nuanced mechanisms involved in both immune attack and evasion induced by anti-PD-L1-CRT with single cell spatial transcriptome. Methods: Xenium is a cutting-edge single-cell spatial analysis tool that enables pathology-based and single-cell analyses while preserving spatial information. In our study, we used Xenium to identify the tumour microenvironment (TME), immune dynamics, and residual cancer cells at the single-cell level following treatment with anti-PD-L1-CRT. Results: Posttreatment alterations included a significant increase in CXCL9+ cells and CXCL13 + T cells, particularly around tumour cells. Additionally, we discovered that CXCL13 + T cells directly impact cancer cells in the posttreatment environment. Moreover, we identified clusters of immune-cold cancer cells posttreatment, revealing their activation of DNA repair pathways and high proliferative capacity. The novel spatial analysis tool Xenium enabled identification of the immune environment at the single-cell level following treatment with anti-PD-L1-CRT, elucidating its characteristics. Conclusions: These findings suggest potential advancements in developing new treatments to improve posttreatment immune responses and address resistance challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Spatial transcriptomics (ST) is evolving to provide higher resolution and multimodal integration, with tools like Xenium enabling single-cell spatial analysis of gene expression (Sakai et al., 2025).”
From Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review (2026) · cites this paper as Sakai et al., 2025
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Xenium was used to study the TME after radiotherapy combined with anti-PD-L1 therapy, revealing an increase in CXCL9+ cells and CXCL13 + T cells around tumor cells (Sakai et al., 2025).”
From Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review (2026) · cites this paper as Sakai et al., 2025
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhu, X., Cao, Y., Liu, W., Ju, X., Zhao, X., Jiang, L., Ye, Y., Jin, G., & Zhang, H. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00286-2 · Cited by 75
RetractedDurvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119 · cited 1×
“Recently, accumulating evidence has revealed that immune responses and immunological cell death also contribute to the antitumour effect of RT [1, 2].”
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798 · cited 1×
“Notably, addition of anti-PD-L1 therapy signi fi cantly improved the effect of CRT on non-small cell lung cancer (NSCLC) in a phase III study [6, 7].”
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., Bogart, J., Hu, C., Forster, K., Magliocco, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71207-0 · Cited by 2,015
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737 · cited 1×
“Recently, accumulating evidence has revealed that immune responses and immunological cell death also contribute to the antitumour effect of RT [1, 2].”
(2010) · Nature Cell Biology · doi:10.1038/ncb0510-413b · Cited by 1,604
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Inflammatory microenvironment remodelling by tumour cells after radiotherapy
McLaughlin, M., Patin, E. C., Pedersen, M., Wilkins, A., Dillon, M. T., Melcher, A. A., & Harrington, K. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0246-1 · Cited by 883
Cited by
Thyroid cancer: From molecular insights to therapy (Review)
Li, Z., Wang, N., Li, X., Xie, Y., Dou, Z., Xin, H., Lin, Y., Si, Y., Feng, T., & Wang, G. (2025) · Oncology Letters · doi:10.3892/ol.2025.15266 · Cited by 25
“…have demonstrated that combined radiotherapy and anti‑PD‑L1 treatment induces the formation of spatially adjacent syner‑ gistic units comprising CXCL13 + CD8 + T cells and CXCL9 + macrophages, whose effector molecules, including granzyme B and IFN‑ γ , directly suppress tumor growth (291,292).”
Shi, T., Guo, Y., Tang, X., Liu, Z., Guo, Q., Fang, T., Xu, S., & Zhuang, Z. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101348 · Cited by 11
Church, M., Marshall, G. B., & Krebs, M. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00684 · Cited by 4
Kang, D. (2026) · Antioxidants · doi:10.3390/antiox15060782 · Cited by 2
Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review
Chen, S., Tu, L., & Chen, Q. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1898418 · Cited by 1
“Spatial transcriptomics (ST) is evolving to provide higher resolution and multimodal integration, with tools like Xenium enabling single-cell spatial analysis of gene expression (Sakai et al., 2025).”
Metadata
- Authors
- Sakai, S. A., Oyoshi, H., Nakamura, M., Taki, T., Nomura, K., Hojo, H., Hirata, H., Motegi, A., Nakamura, Y., Zenkoh, J., Aokage, K., Hamada, A., Kojima, M., Kuwata, T., Tsuchihara, K., Akimoto, T., Soh, J., Mitsudomi, T., Tsuboi, M., Ishii, G., Suzuki, Y., Suzuki, A., Yamashita, R., & Kageyama, S.-I.
- Affiliations
- National Cancer Center Exploratory Oncology Research & Clinical Trial Center (JP)
- National Cancer Center Hospital East (JP)
- The University of Tokyo (JP)
- Kindai University (JP)
- Kyoto Prefectural University of Medicine (JP)
- Corresponding author
- Suzuki, Ayako
- Yamashita, Riu
- Kageyama, Shun-Ichiro
- ORCID
- Sakai, Shunsuke A.
- Oyoshi, Hidekazu
- Nakamura, Masaki
- Taki, Tetsuro
- Nomura, Kotaro
- Hojo, Hidehiro
- Hirata, Hidenari
- Motegi, Atsushi
- Nakamura, Yuka
- Zenkoh, Junko
- Aokage, Keiju
- Hamada, Akira
- Kojima, Motohiro
- Kuwata, Takeshi
- Tsuchihara, Katsuya
- Akimoto, Tetsuo
- Soh, Junichi
- Mitsudomi, Tetsuya
- Tsuboi, Masahiro
- Ishii, Genichiro
- Suzuki, Yutaka
- Suzuki, Ayako
- Kageyama, Shun-Ichiro
- Venue
- British Journal of Cancer
- Published
- 2025-07-16
- Volume
- 133
- Issue
- 6
- Pages
- 795-808
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC12449477
- OpenAlex
- W4412481978
- Cited by
- 15
- References
- 55
- Citations by year
- 2026: 12 · 2025: 3
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- British Journal of Cancer (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology (21K07582)
- MEXT | Japan Science and Technology Agency (JPMJSP2108)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- non-small cell lung cancer, PD-L1 blockade, chemoradiotherapy, tumor microenvironment, single-cell spatial transcriptomics, Xenium, residual tumor cells, immune evasion, DNA repair pathways, tumor cell proliferation, antitumor immunity
- MeSH terms
- Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, T-Lymphocytes, Cell Line, Tumor, Chemokine CXCL9, Chemokine CXCL13, Single-Cell Analysis, Tumor Microenvironment, Chemoradiotherapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy. https://app.cochat.ai/papers/10.1038/s41416-025-03088-0
- The paper
- Sakai, S. A., Oyoshi, H., Nakamura, M., Taki, T., Nomura, K., Hojo, H., Hirata, H., Motegi, A., Nakamura, Y., Zenkoh, J., Aokage, K., Hamada, A., Kojima, M., Kuwata, T., Tsuchihara, K., Akimoto, T., Soh, J., Mitsudomi, T., Tsuboi, M., . . . Kageyama, S.-I. (2025). Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy. British Journal of Cancer. https://doi.org/10.1038/s41416-025-03088-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.